actinic keratosis

(redirected from Actinic keratoses)
Also found in: Dictionary, Medical.
Related to Actinic keratoses: basal cell carcinoma, squamous cell carcinoma, seborrheic keratosis
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to actinic keratosis

an overgrowth of skin layers resulting from extended exposure to the sun

Related Words

References in periodicals archive ?
as a well-tolerated field-directed therapy, suitable for the long-term treatment of actinic keratoses, showing an overall high complete clearance rate after one year.
A direct clinical comparator study testing the clearance of all actinic keratoses of a patient proved the strong superiority of AmeluzA compared to its closest competitor.
Actinic keratoses often appear on bald scalps, face, ears, lips, backs of the hands, forearms, or any other areas exposed to the sun.
Actinic keratoses can be considered a precursor to squamous cell carcinoma (SCC).
The research team, led by University of Alabama at Birmingham senior scientist Craig Elmets, evaluated the efficacy and safety of celecoxib as a chemo-preventive agent for actinic keratoses.
There are two important things to consider with actinic keratoses.
Many feel that actinic keratoses are precancerous lesions.
The study demonstrated that actinic keratoses (AKs) are common precursors not only to squamous cell carcinoma (SCC) but also to basal cell carcinoma (BCC), contrary to conventional wisdom, Dr.
Actinic keratoses are typically found on those parts of the body that receive the most sun exposure, such as the face, ears, lips, neck, back of hands, and forearms.
Around 96 per cent have never heard of actinic keratoses and almost half would ask a friend or relative to look at a mark on their skin rather than a health professional.
Ninety six per cent of people had not heard of actinic keratoses.
The research, by NOP, found 96 per cent of people in Britain had not heard of actinic keratoses.
Actinic keratoses are common skin lesions among middle-aged people, usually caused by overexposure to the sun.
The Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding marketing authorization of Zyclara (treatment of actinic keratoses on large skin areas).